Crocs: Best-In-Class Operating Margins And ROE

Miller Value Funds highlights Crocs as a high-quality staple trading at cyclical valuations despite strong margins. Explore ...
The Manila Times

Unaudited consolidated interim accounts for the fourth quarter and twelve months of 2025

Q4/25Q4/24yoy12m/2512m/24yoySupermarkets157.0164.1-4.3%611.9610.40.3%Department ...

Should You Be Confident in Chipotle Mexican Grill’s (CMG) Growth Trajectory?

Sustainable Growth Advisers (SGA), an investment management company, released its third-quarter investor letter for its “U.S. Large Cap Growth Strategy.” A copy of the letter can be downloaded here.

Andrew Hill Investment Advisors Q4 2025 Client Letter

Andrew Hill Investment Advisors reports that client portfolios achieved double digit gains during 2025. Review our defensive ...
PharmiWeb

Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan

Strategic collaboration expands taletrectinib global reach with a leading oncology partnerEisai will receive exclusive development, registration and commercialization rights for taletrectinib for the ...
The Manila Times

Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs ...

Eisai And Nuvation Bio Enter Into Exclusive Licensing Agreement For Taletrectinib In Europe And Additional Countries Outside The U.S., China And Japan

Eisai And Nuvation Bio Enter Into Exclusive Licensing Agreement For Taletrectinib In Europe And Additional Countries Outside The U.S., China And Japan. Eisai and Nuvation Bio Enter into Exclusive ...

Basilea Pharmaceutica AG: Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections

Allschwil, Switzerland, January 07, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial ...

Prokaryotics and Basilea enter collaboration to develop a novel broad-spectrum antifungal for severe invasive infections

Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement with Basilea Pharmaceutica Ltd, Allschwil ...
Insurance Insider

2026: The year reinsurance FOMO is put to the test?

It is no surprise that reinsurers were taken aback by the pace of reductions, as these kind of rate cuts have not been seen ...